A review on the role of MicroRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma

Pancreas

Volumn 41, Issue 5, 2012, Pages 671-677

  Papaconstantinou, Ioannis G ^a   Lykoudis, Panagis M ^a   Gazouli, Maria ^b   Manta, Asimina ^a   Polymeneas, Giorgos ^a   Voros, Dionysios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antagomirs; MicroRNAs; Oncomirs; Pancreatic adenocarcinoma

Indexed keywords

ANTAGOMIR; ANTISENSE OLIGONUCLEOTIDE; BRCA2 PROTEIN; GEMCITABINE; MICRORNA; MICRORNA 1; MICRORNA 107; MICRORNA 10B; MICRORNA 122; MICRORNA 132; MICRORNA 143; MICRORNA 146A; MICRORNA 155; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 21; MICRORNA 221; MICRORNA 29B; MICRORNA 34A; PROTEIN P16; PROTEIN P53; RNA INDUCED SILENCING COMPLEX; VASCULOTROPIN;

ANTISENSE THERAPY; BIOGENESIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CHEMOSENSITIVITY; ENDOSCOPIC ECHOGRAPHY; GENE SILENCING; HUMAN; INTERACTIONS WITH RNA; LIVER METASTASIS; METASTASIS POTENTIAL; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA SYNTHESIS; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MICRORNAS; MODELS, GENETIC; NEOPLASM METASTASIS; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR BURDEN;

EID: 84863645097     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31823c9d21     Document Type: Review

References (88)

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854.
2. Lee RC, Ambros V. An extensive class ofsmall RNAs in Caenorhabditis elegans. Science. 2001;294(5543):862-864.
3. Llave C, Kasschau KD, Rector MA, et al. Endogenous and silencing-associated small RNAs in plants. Plant Cell. 2002;14(7):1605-1619.
4. Rhoades MW, Reinhart BJ, Lim LP, et al. Prediction of plant microRNA targets. Cell. 2002;110(4):513-520.
5. Lim LP, Glasner ME, Yekta S, et al. Vertebrate microRNA genes. Science. 2003;299(5612):1540.
6. Palatnik JF, Allen E, Wu X, et al. Control of leaf morphogenesis by microRNAs. Nature. 2003;425(6955):257-263.
7. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6(5):376-385.
8. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425(6956):415-419.
9. Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231-235.
10. Gregory RI, Yan KP, Amuthan G, et al. The microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432(7014):235-240.
11. Han J, Lee Y, Yeom KH, et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004;18(24):3016-3027.
12. Landthaler M, Yalcin A, Tuschl T. The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol. 2004;14(23):2162-2167.
13. Okamura K, Hagen JW, Duan H, et al. The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell. 2007;130(1):89-100.
14. Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. Nature. 2007;448(7149):83-86.
15. Berezikov E, Chung WJ, Willis J, et al. Mammalian mirtron genes. Mol Cell. 2007;28(2):328-336.
16. Chan SP, Slack FJ. And now introducing mammalian mirtrons. Dev Cell. 2007;13(5):605-607.
17. Grishok A, Pasquinelli AE, Conte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell. 2001;106(1):23-34.
18. Ketting RF, Fischer SE, Bernstein E, et al. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 2001;15(20):2654-2659.
19. Knight SW, Bass BL. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans. Science. 2001;293(5538):2269-2271.
20. Du T, Zamore PD. microPrimer: the biogenesis and function of microRNA. Development. 2005;132(21):4645-4652.
21. Pillai RS, Bhattacharyya SN, Artus CG, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 2005;309(5740):1573-1576.
22. Kiriakidou M, Tan GS, Lamprinaki S, et al. An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell. 2007;129(6):1141-1151.
23. Chendrimada TP, Finn KJ, Ji X, et al. MicroRNA silencing through RISC recruitment of eIF6. Nature. 2007;447(7146):823-828.
24. Nottrott S, Simard MJ, Richter JD. Human let-7a miRNA blocks protein production on actively translating polyribosomes. Nat Struct Mol Biol. 2006;13(12):1108-1114.
25. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell. 2008;132(1):9-14.
26. Maroney PA, Yu Y, Fisher J, et al. Evidence that microRNAs are associated with translating messenger RNAs in human cells. Nat Struct Mol Biol. 2006;13(12):1102-1107.
27. Petersen CP, Bordeleau ME, Pelletier J, et al. Short RNAs repress translation after initiation in mammalian cells. Mol Cell. 2006;21(4):533-542.
28. Bagga S, Bracht J, Hunter S, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 2005;122(4):553-563.
29. Behm-Ansmant I, Rehwinkel J, Doerks T, et al. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev. 2006;20(14):1885-1898.
30. Eulalio A, Rehwinkel J, Stricker M, et al. Target-specific requirements for enhancers of decapping in miRNA-mediated gene silencing. Genes Dev. 2007;21(20):2558-2570.
31. Giraldez AJ, Mishima Y, Rihel J, et al. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science. 2006;312(5770):75-79.
32. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769-773.
33. Wu L, Belasco JG. Micro-RNA regulation of the mammalian lin-28 gene during neuronal differentiation of embryonal carcinoma cells. Mol Cell Biol. 2005;25(21):9198-9208.
34. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A. 2006;103(11):4034-4039.
35. Chu CY, Rana TM. Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54. Plos Biol. 2006;4(7):e210.
36. Eulalio A, Behm-Ansmant I, Izaurralde E. P bodies: at the crossroads of post-transcriptional pathways. Nat Rev Mol Cell Biol. 2007;8(1):9-22.
37. Eulalio A, Behm-Ansmant I, Schweizer D, et al. P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol Cell Biol. 2007;27(11):3970-3981.
38. Humphreys DT, Westman BJ, Martin DI, et al. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly (A) tail function. Proc Natl Acad Sci U S A. 2005;102(47):16961-16966.
39. Parker R, Sheth U. P bodies and the control of mRNA translation and degradation. Mol Cell. 2007;25(5):635-646.
40. Cai Y, Yu X, Hu S, et al. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 2009;7(4):147-154.
41. Steitz JA, Vasudevan S. miRNPs: versatile regulators of gene expression in vertebrate cells. Biochem Soc Trans. 2009;37(Pt 5):931-935.
42. Heneghan HM, Miller N, Kerin MJ. Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol. 2010;28(29):e573-e574; author reply e575-576.
43. Jay C, Nemunaitis J, Chen P, et al. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007;26(5):293-300.
44. Garber K. No miR hype: MicroRNA's cancer role expands. J Natl Cancer I. 2006;98(13):885-887.
45. Ross JS, Carlson JA, Brock G. miRNA: the new gene silencer. Am J Clin Pathol. 2007;128(5):830-836.
46. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005;438(7068):685-689.
47. Tong AW, Nemunaitis J. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther. 2008;15(6):341-355.
48. Yang N, Kaur S, Volinia S, et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008;68(24):10307-10314.
49. National Cancer Institute. SEER Stat Fact Sheets: Pancreas. 2011;17:Available at: http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed 22/03/2011, 2011.
50. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
51. Nakeeb A, Lillemoe KD. Neoplasms of the exocrine pancreas. In: Mulholland MW, Lillemoe KD, eds. Greenfield's Surgery: Scientific Principles and Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:837-856.
52. Zyromski NJ, Nakeeb A, Lillemoe KD. Cancer of the pancreas: surgical management. In: Silberman H, Silberman AW, eds. Principles and Practice of Surgical Oncology: Multidisciplinary Approach to Difficult Problems. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:676-693.
53. Park DJ, Lenz HJ. Cancer of the pancreas: adjuvant and neo-adjuvant therapy. In: Silberman H, Silberman AW, eds. Principles and Practice of Surgical Oncology: Multidisciplinary Approach to Difficult Problems. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:694-705.
54. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24(29):4677-4684.
55. Dillhoff M, Liu J, Frankel W, et al. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008;12(12):2171-2176.
56. Habbe N, Koorstra JB, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009;8(4):340-346.
57. Zhang S, Cai X, Huang F, et al. Effect of trichostatin a on viability and microRNA expression in human pancreatic cancer cell line BxPC-3. Exp Oncol. 2008;30(4):265-268.
58. Moriyama T, Ohuchida K, Mizumoto K, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther. 2009;8(5):1067-1074.
59. Park JK, Lee EJ, Esau C, et al. Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009;38(7):e190-e199.
60. Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70(11):4528-4538.
61. Hwang JH, Voortman J, Giovannetti E, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One. 2010;5(5):e10630.
62. Bhatti I, Lee A, James V, et al. Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2011;15(1):199-208.
63. Bao B, Ali S, Kong D, et al. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One. 2011;6(3):e17850.
64. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26(30):4442-4452.
65. Basu A, Alder H, Khiyami A, et al. MicroRNA-375 and microRNA-221: potential noncoding RNAs associated with antiproliferative activity of benzyl isothiocyanate in pancreatic cancer. Genes Cancer. 2011;2(2):108-119.
66. Xia QS, Ishigaki Y, Zhao X, et al. Human SMG-1 is involved in gemcitabine-induced primary microRNA-155/BIC up-regulation in human pancreatic cancer PANC-1 cells. Pancreas. 2011;40(1):55-60.
67. Lee KH, Lotterman C, Karikari C, et al. Epigenetic silencing of microRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology. 2009;9(3):293-301.
68. Kent OA, Mullendore M, Wentzel EA, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther. 2009;8(21):2013-2024.
69. Ikenaga N, Ohuchida K, Mizumoto K, et al. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17(12):3120-3128.
70. Yu J, Ohuchida K, Mizumoto K, et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer. 2010;9:169.
71. Yu J, Ohuchida K, Mizumoto K, et al. MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis and involved in cancer cell proliferation and invasion. Cancer Biol Ther. 2010;10(8):748-757.
72. Jutooru I, Chadalapaka G, Abdelrahim M, et al. Methyl 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol. 2010;78(2):226-236.
73. Park JK, Henry JC, Jiang J, et al. miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun. 2011;406(4):518-523.
74. Kong X, Du Y, Wang G, et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 2011;56(2):602-609.
75. Laconti JJ, Shivapurkar N, Preet A, et al. Tissue and serum microRNAs in the Kras transgenic animal model and in patients with pancreatic cancer. PLoS One. 2011;6(6):e20687.
76. Preis M, Gardner TB, Gordon SR, et al. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011;17(17):5812-5821.
77. Zhao WG, Yu SN, Lu ZH, et al. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 2010;31(10):1726-1733.
78. Yu S, Lu Z, Liu C, et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010;70(14):6015-6025.
79. Yan HJ, Wu JX, Liu WS, et al. MicroRNA-20a overexpression inhibited proliferation and metastasis of pancreatic carcinoma cells. Hum Gene Ther. 2010;21(12):1723-1734.
80. Liffers ST, Munding JB, Vogt M, et al. MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Invest. 2011;91(10):1472-1479.
81. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. Plos One. 2009;4(8):e6816.
82. Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor micrornas using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 2011;10(8):1470-1480.
83. Ohuchida K, Mizumoto K, Kayashima T, et al. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol. 2011;18(8):2381-2387.
84. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901-1908.
85. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120(5):1046-1054.
86. Ibberson D, Benes V, Muckenthaler MU, et al. RNA degradation compromises the reliability of microRNA expression profiling. BMC Biotechnol. 2009;9:102.
87. Kim J, Choi NE, Oh SJ, et al. Combined expression of miR-122a, miR-1, and miR-200b can differentiate degraded RNA samples from liver, pancreas, and stomach. Pathol Int. 2011;61(2):67-72.
88. Jung DE, Wen J, Oh T, et al. Differentially expressed microRNAs in pancreatic cancer stem cells. Pancreas. 2011;40(8):1180-1187.